IP Verse

Crystalline Polymorphs Of The Free Base Of 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-Yl)Pyridin-3-Yl)Methoxy)Benzaldehyde - EP3102208

The patent EP3102208 was granted to Blood Therapeutics on Jul 17, 2024. The application was originally filed on Feb 5, 2015 under application number EP15746995A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3102208

BLOOD THERAPEUTICS
Application Number
EP15746995A
Filing Date
Feb 5, 2015
Status
Patent Maintained As Amended
Jun 14, 2024
Publication Date
Jul 17, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BULLE DROct 13, 2021KUTZENBERGER WOLFF & PARTNERADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2013190315
DESCRIPTIONWO2013102142
INTERNATIONAL-SEARCH-REPORTUS2013072472
INTERNATIONAL-SEARCH-REPORTUS2013190315
INTERNATIONAL-SEARCH-REPORTUS2013190316
OPPOSITIONWO2013102142
SEARCHWO2013102142

Non-Patent Literature (NPL) Citations (8) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- Stephen Byrn ET AL, "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", Pharmaceutical Research, (19950101), vol. 12, no. 7, doi:10.1023/A:1016241927429, pages 945 - 954, XP055531015
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OXBRYTA safely and effectively. See full prescribing information for OXBRYTA", FDA, (20190101), pages 1 - 16, FDA, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf, (20211119), XP055863420
OPPOSITION- Augustijns Patrick, Et Al, "Solvent systems for crystallization and polymorph selection", Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics, Springer, (20070101), pages 91 - 94, XP055863415
OPPOSITION- Blacker John A, Et Al, "Salt screening and Selection", Pharmaceutical Process Development, Current Chemical and Engineering Challenges, RSC, (20110101), pages 300 - 309, XP055863414
OPPOSITION- Han Chao, Et Al, "Crystal forms salts and cocrystals", Evaluation of Drug Candidates for Preclinical Development Pharmacokinetics, Metabolism, Pharmaceutics, and Toxicology, Wiley, (20100101), pages 209 - 210, XP055863417
OPPOSITION- M.R. CAIRA, "Crystalline Polymorphism of Organic Compounds", Topics in Current Chemistry, (19980000), vol. 198, doi:10.1007/3-540-69178-2_5, pages 163 - 208, XP008166276
OPPOSITION- Stephen Byrn et al, "Pharmaceutical Solids: A strategic Approach to Regulatory Considerations", Pharmaceutical Research, Springer US, New York, New York, (19950701), vol. 12, no. 07, doi:10.1023/A:1016241927429, ISSN 0724-8741, pages 945 - 954, XP000996386
SEARCH- CAIRA, "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, (1998), vol. 198, ISSN 0340-1022, pages 163 - 208, XP008166276 [Y] 1-18 * page 165 - page 166 * * 3.1 Review of Preparative Methods; page 177 - page 180 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents